Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

Part of paid clinical trials in Dublin, California.

Sponsor
Cytrellis Biosystems, Inc.
Study ID
NCT07224880
Status
Recruiting
Apply to this trial

Conditions

  • Gene Expression
  • Skin Laxity
  • glp1 Agonist

Eligibility Criteria

Sex
ALL
Age
30 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • ellacor — DEVICE
    dermal non-thermal micro-coring device

Study Details

The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity

Key Dates

Start date
Oct 14, 2025
Status verified
Sep 2025
Primary completion
Jan 30, 2026
Completion
Feb 28, 2026

Study Design

Enrollment
10 participants (estimated)

Arms

  • Arm: GLP1 Patients
    Patients have lost at least 10% of their baseline body weight from taking a GLP-1 receptor agonist

Primary Outcome Measure

Safety and Outcomes [ Time Frame: study time frame ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Tri Valley Plastic SurgeryDublinCalifornia94568
Pooja Kachhia
[email protected]
925-701-9302
McKenzie Dixon
[email protected]
925-701-9302
Steven Williams, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Dublin, CA

By research site
Tri Valley Plastic Surgery· Dublin, CA

Related Studies